Genetic variants in microRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival, and treatment response

Cancer Research

Volumn 70, Issue 23, 2010, Pages 9765-9776

  Liang, Dong ^a   Meyer, Larissa ^b   Chang, David W ^b   Lin, Jie ^b   Pu, Xia ^b   Ye, Yuanqing ^b   Gu, Jian ^b   Wu, Xifeng ^b   Lu, Karen ^b  

^a TEXAS SOUTHERN UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA;

3' UNTRANSLATED REGION; ADULT; ARTICLE; BINDING SITE; BIOSYNTHESIS; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CANCER THERAPY; CONTROLLED STUDY; FEMALE; GENE DOSAGE; GENE INTERACTION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HOMOZYGOSITY; HUMAN; INTRON; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; BINDING SITES; BIOSYNTHETIC PATHWAYS; CELL LINE, TUMOR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOKINES; MICRORNAS; MIDDLE AGED; ODDS RATIO; OVARIAN NEOPLASMS; PLATELET-DERIVED GROWTH FACTOR; POLYMORPHISM, SINGLE NUCLEOTIDE; RIBONUCLEOPROTEINS, SMALL NUCLEAR; RISK ASSESSMENT; RISK FACTORS; TRANSFECTION; TREATMENT OUTCOME;

EID: 78649977193     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0130     Document Type: Article

References (49)

1. American Cancer Society. Cancer Facts and Figures. Atlanta, GA: American Cancer Society; 2008. p. 1-68.
2. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Gent 2001;68:700-10.
3. Drake AC, Campbell H, Porteous MEM, Dunlop MG. The contribution of DNA mismatch repair gene defects to the burden of gynecological cancer. Int J Gynecol Cancer 2003;13:262-77. (Pubitemid 38222573)
4. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are miroRNA targets. Cell 2005;12:15-20.
5. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8.
6. Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A, et al. MicroRNA exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A 2006;103:9136-41.
7. Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nature Cell Biol 2008;10:202-10.
8. Yang H, Dinney CP, Ye Y, Zhu Y, Grossman HB, Wu X. Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. Cancer Res 2008;68:2530-7. (Pubitemid 351521830)
9. Horikawa Y, Wood CG, Yang H, Zhao H, Ye Y, Gu J, et al. Single nucleotide polymorphisms of microRNA machinery genes modify the risk of renal cell carcinoma. Clin Cancer Res 2008;14:7956-62.
10. Ye Y, Wang KK, Gu J, Yang H, Lin J, Ajani JA, et al. Genetic variations in microRNA-related genes are novel susceptibility loci for esophageal cancer risk. Cancer Prev Res 2008;1:460-9.
11. Bartel DP. MicroRNA: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
12. Wu X, Spitz MR, Lee J, Lippman SM, Ye Y, Yang H, et al. Novel susceptibility loci for second primary tumors/recurrence in early-stage head and neck cancer patients: large scale evaluation of genetic variants. Cancer Prev Res 2009;2:617-24.
13. Quaye L, Gayther SA, Ramus SJ, Di Cioccio RA, McGuire V, Hogdall E, et al. The effects of common genetic variants in oncogenes on ovarian cancer survival. Clin Cancer Res 2008;14:5833-9.
14. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007;67:8699-707.
15. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008;68:425-33. (Pubitemid 351380068)
16. Charroux B, Pellizzoni L, Perkinson RA, Yong J, Shevchenko A, Mann M, et al. Gemin4, a novel component of the SMN complex that is found in both gems and nucleoli. J Cell Biol 2000;148:1177-86.
17. Scherz-Shouval R, Shvets E, Fass W, Shorer H, Gil L, Elazar Z. Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. The EMBO J 2007;26:1749-60. (Pubitemid 46624042)
18. Bialik S, Kimchi A. Autophagy and tumor suppression: recent advances in understanding the link between autophagic cell death pathways and tumor development. Adv Exp Med Biol 2008;615:177-200.
19. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature 2008;451:1069-75. (Pubitemid 351317450)
20. Court MH, Hazarika S, Krishnaswamy S, Finel M, Williams JA. Novel polymorphic human UDP-glucuronosyltransferase 2A3: cloning, functional characterization of enzyme variants, comparative tissue expression, and gene induction. Mol Pharmacol 2008;74:744-54.
21. Girard H, Butler LM, Villeneuve L, Millikan RC, Sinha R, Sandler RS, et al. UGT1A1 and UGT1A9 functional variants, meat intake, and colon cancer, among Caucasians and African-Americans. Mut Res 2008;644:56-63.
22. Tanase P. Caveolin-1: a marker for pancreatic cancer diagnosis. Expert Rev Mol Diagn 2008;8:395-404. (Pubitemid 351962086)
23. Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 2009;6:201-5.
24. Bell DA. Origins and molecular pathology of ovarian cancer.Mod Pathol 2005;Suppl2:S19-32.
25. Furukawa T, Sunamura M, Horil A. Molecular mechanisms of pancreatic carcinogenesis. Cancer Sci 2006;97:1-7.
26. Saif MW, Shah M. K-ras mutations in colorectal cancer: a practice changing discovery. Clin Adv Hematol Oncol 2009;7:45-53.
27. Reimer D, Sadr S, Wiedemair A, Goebel G, Concin N, Hofstetter G, et al. Expression of the E2F family of transcription factors and its clinical relevance in ovarian cancer. Ann N Y Acad Sci 2006;109:270-81. (Pubitemid 47092243)
28. Yamano Y, Uzawa K, Saito K, Nakashima D, Kasamatsu A, Koike H, et al. Identification of cisplatin-resistance related genes in head and neck squamous cell carcinoma. Int J Cancer 2010;126:437-49.
29. Crawford Y, Kasman I, Yu L, Zhong C, Wu X, Modrusan Z, et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment.Cancer Cell 2009;15:21-34.
30. Anderberg C, Li H, Fredriksson L, Andrae J, Betsholtz C, Li X, et al. Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts. Cancer Res 2009;69:369-78.
31. Gal H, Pandi G, Kanner AA, Ram Z, Lithwick-Yanai G, Amariglio N, et al. MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells. Biochem Biophys Res Commun 2008;376:86-90.
32. Zhou M, McFarland-Mancini MM, Funk HM, Husseinzadeh N, Mounajjed T, Drew AF. Toll-like receptor expression in normal ovary and ovarian tumors. Cancer Immunol Immunother 2009;58:1375-85.
33. Szczepanski MJ, Czystowka M, Szajnik M, Harasymczuk M, Boyiadzis M, Kruk-Zagajewska A, et al. Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res 2009;69:3105-13.
34. Zeng-Rong N, Paterson J, Alpert L, Tsao MS, Viallet J, Alaoui-Jamali MA. Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy. Cancer Res 1995;55:4760-4.
35. Bosken CH, Wei Q, Amos CI, Spitz MR. An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer Inst 2002;94:1091-9. (Pubitemid 34830729)
36. Hildebrandt MA, Gu J, Wu X. Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opin Drug Metab Toxicol 2009;5:745-55.
37. Enomoto T, Weghorst CM, Inoue M, Tanizawa O, Rice JM. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol 1991;139:777-85.
38. Cuatrecasas M, Erill N, Musulen E, Costa I, Matias-Guiu X, Prat J. Kras mutations in nonmucinous ovarian epithelial tumors: a molecular analysis and clinicopathologic study of 144 patients. Cancer 1998;82:1088-95. (Pubitemid 28136522)
39. Fujita M, Enomoto T, Murata Y. Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes. Mol Cell Endocrinol 2003;202:97-9. (Pubitemid 36593399)
40. Mayr D, Hirschmann A, Löhrs U, Diebold J. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol 2006;103:883-7. (Pubitemid 44821309)
41. Kuo KT, Guan B, Feng Y, Mao TL, Chen X, Jinawath N, et al. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res 2009;69:4036-42.
42. Davidson NE, Sukumar S. Of snail, mice, and women. Cancer Cell 2005;8:173-74.
43. Blechschmidt K, Sasser S, Schmalfeldt B, Schuster T, Höfler H, Becker KF. The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients. Br J Cancer 2008;98:489-95. (Pubitemid 351161237)
44. Marchitti SA, Brocker C, Dimitrios S, Vasiliou V. Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert Opin Drug Metab Toxicol 2008;4:697-720. (Pubitemid 352003194)
45. Ran D, Schubert M, Pietsch L, Taubert I, Wuchter P, Eckstein V, et al. Aldehyde dehydrogenase activity among primary leukemia cells is associated with stem cell features and correlates with adverse clinical outcomes. Exp Hematol 2009;37:1423-34.
46. Cui R, Kamatani Y, Takahashi A, Usami M, Hosono N, Kawaguchi T, et al. Functional variants in ADH1B and ALDH2 coupled with alcohol and smoking synergistically enhance esophageal cancer risk. Gastroenterology 2009;137:1768-75.
47. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007;1:555-67.
48. Otero-Rey EM, Somoza-Martín M, Barros-Angueira F, García-García A. Intracellular pH regulation in oral squamous cell carcinoma is mediated by increased V-ATPase activity via over-expression of the ATP6V1C1 gene. Oral Oncol 2008;44:193-9. (Pubitemid 351193013)
49. Allison SJ, Milner J. SI-RT3 is pro-apoptotic and participates in distinct basal apoptotic pathways. Cell Cycle 2007;6:2669-77. (Pubitemid 350224051)